Literature DB >> 25859479

The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.

Apar Jindal1, V Viswambhar2, Arun Babu V1.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common disease causing significant socioeconomic burden. COPD patients, commonly smokers develop resistance to inhaled steroids attributed to deficiency of histone deacetylase 2 (HDAC2). The study of relationship between systemic inflammation and functional performance demonstrated that increased CRP level is inversely related to six minute walk distance (SMWD) and Forced Expired Volume in one second (FEV1). Theophylline restores HDAC2 activity thereby unlocking steroid resistance and potentiating inhaled corticosteroids (ICS) action culminating in reduced airway inflammation and mortality. AIM: To study the effects of addition of Theophylline to the combination of Formoterol plus Budesonide on various objective and subjective parameters in moderate to severe COPD patients and to assess the safety profile of the combination. Setting and Study design: A single blinded, prospective, randomized, placebo controlled study at a tertiary care hospital in Jaipur, India.
MATERIALS AND METHODS: Fifty eight patients diagnosed with moderate to severe COPD were randomized into two groups. Group A patients received Formoterol 24μg plus budesonide 800μg daily in divided doses along with Theophylline while group B patients received Formoterol 24μg plus budesonide 800μg daily in divided doses along with placebo tablets. Both groups were followed up on 15th, 30th &60th day. During every visit all patients were assessed subjectively (symptom scoring) and objectively (spirometry, CRP, SMWT) and adverse effects if any were recorded. The obtained data subject to statistical analysis using"Graph pad Instat3" software.
RESULTS: Statistically significant improvement with a decline in total symptom score (p < 0.0001) was found with respect to "Night symptoms"&amp;"SOB on rising" in group A. Theophylline group showed significant improvement in SMWD and FEV1.Mean fall in CRP was greater in Group A (not statistically significant). No side effects requiring withdrawal of drug were noted with Theophylline.
CONCLUSION: Addition of Theophylline to Formoterol plus Budesonide reduces dyspnea, improves exercise performance and pulmonary functions in moderate to severe COPD. Further studies are required to explore if reduced dosage would have equal efficacy with better safety and tolerability profile.

Entities:  

Keywords:  COPD; CRP; Histone deacetylase; Theophylline

Year:  2015        PMID: 25859479      PMCID: PMC4378761          DOI: 10.7860/JCDR/2015/10803.5527

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  27 in total

1.  A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

Authors:  Kazuhiro Ito; Sam Lim; Gaetano Caramori; Borja Cosio; K Fan Chung; Ian M Adcock; Peter J Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-17       Impact factor: 11.205

2.  Theophylline for COPD.

Authors:  P J Barnes
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

Review 3.  Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review.

Authors:  Eliane Cristina Zacarias; Aldemar Araújo Castro; Sônia Cendon
Journal:  J Bras Pneumol       Date:  2007 Mar-Apr       Impact factor: 2.624

4.  Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease.

Authors:  P Thomas; J A Pugsley; J H Stewart
Journal:  Chest       Date:  1992-01       Impact factor: 9.410

5.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

6.  Salmeterol plus theophylline combination therapy in the treatment of COPD.

Authors:  R L ZuWallack; D A Mahler; D Reilly; N Church; A Emmett; K Rickard; K Knobil
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

7.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

Authors:  G Boyd; A H Morice; J C Pounsford; M Siebert; N Peslis; C Crawford
Journal:  Eur Respir J       Date:  1997-04       Impact factor: 16.671

8.  C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.

Authors:  J P de Torres; E Cordoba-Lanus; C López-Aguilar; M Muros de Fuentes; A Montejo de Garcini; A Aguirre-Jaime; B R Celli; C Casanova
Journal:  Eur Respir J       Date:  2006-02-02       Impact factor: 16.671

9.  Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; Paige Lacy; Ernest York; S F Paul Man
Journal:  Am J Respir Crit Care Med       Date:  2004-06-30       Impact factor: 21.405

10.  Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study.

Authors:  M R Alexander; W L Dull; J E Kasik
Journal:  JAMA       Date:  1980-11-21       Impact factor: 56.272

View more
  6 in total

1.  Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.

Authors:  Graham Devereux; Seonaidh Cotton; Shona Fielding; Nicola McMeekin; Peter J Barnes; Andrew Briggs; Graham Burns; Rekha Chaudhuri; Henry Chrystyn; Lisa Davies; Anthony De Soyza; Simon Gompertz; John Haughney; Karen Innes; Joanna Kaniewska; Amanda Lee; Alyn Morice; John Norrie; Anita Sullivan; Andrew Wilson; David Price
Journal:  JAMA       Date:  2018-10-16       Impact factor: 56.272

2.  Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis.

Authors:  Tiankui Shuai; Chuchu Zhang; Meng Zhang; Yalei Wang; Huaiyu Xiong; Qiangru Huang; Jian Liu
Journal:  PLoS One       Date:  2021-05-24       Impact factor: 3.240

Review 3.  Emerging pharmaceutical therapies for COPD.

Authors:  Sowmya P Lakshmi; Aravind T Reddy; Raju C Reddy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-21

4.  Clinical outcomes of theophylline use as add-on therapy in patients with chronic obstructive pulmonary disease: A propensity score matching analysis.

Authors:  Preyanate Wilairat; Kirati Kengkla; Chaiyawat Thayawiwat; Phongsathorn Phlaisaithong; Supakorn Somboonmee; Surasak Saokaew
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

5.  The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China.

Authors:  Kewu Huang; Yanfei Guo; Jian Kang; Li An; Zeguang Zheng; Lijun Ma; Liping Peng; Hongyang Wang; Rong Su; Yohji Itoh; Chen Wang
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 6.  Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.

Authors:  Leena George; Christopher E Brightling
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.